Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21661235 | 0.88 | TDP1 (0.51) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL904060 | 0.88 | TDP1 (0.65) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3341020 | 0.86 | TDP1 (0.67) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL8959096 | 0.86 | TDP1 (0.68) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL28630680 | 0.84 | TDP1 (0.71) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL28636908 | 0.84 | TDP1 (0.71) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1486465 | 0.84 | TDP1 (0.71) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL9573730 | 0.83 | TDP1 (0.55) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3020258 | 0.82 | TDP1 (0.81) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL569251 | 0.82 | TDP1 (0.74) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119080766-B | Preparation method and application of fluorescent material based on heterocyclic structure | 肇庆创峰高新材料有限公司 | 2025-01-14 | — | — | CN | claimed |
| CN-119080766-A | Preparation method and application of fluorescent material based on heterocyclic structure | 肇庆创峰高新材料有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-112694437-A | Preparation method of chlorpheniramine maleate impurity | 北京悦康科创医药科技股份有限公司 | 2021-04-23 | — | — | CN | claimed |
| CN-108033931-A | A kind of synthetic method of N-Boc piperazines | 山东铂源药业有限公司 | 2018-05-15 | — | — | CN | claimed |
| US-20260007754-A1 | Conjugate Molecules | DIVERSE BIOTECH INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | GENASE THERAPEUTICS B V (NL) | 2025-12-25 | — | — | US | disclosed |
| EP-4370207-B1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12466829-B2 | Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4469461-B1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B V (NL) | 2025-10-15 | — | — | EP | disclosed |
| US-RE50634-E1 | Diaryl macrocycles as modulators of protein kinases | Turning Point Therapeutics, Inc. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4615838-A1 | SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| US-12404281-B2 | Diaryl macrocycles as modulators of protein kinases | Turning Point Therapeutics, Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| US-5604246-A | HAVING POTENCY AGAINST MULTIDRUG RESISTANT TUMORS | BOEHRINGER MANNHEIM ITALIA SPA (IT) | 1997-02-18 | — | — | US | disclosed |
| US-5596097-A | ANTITUMOR AGENTS | THE UNIVERSITY OF VERMONT (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0750619-A1 | HETERO-ANNULATED INDAZOLES | BOEHRINGER MANNHEIM ITALIA S.p.A. (IT) | 1997-01-02 | — | — | EP | disclosed |
| US-5519029-A | ANTITUMOR AGENTS | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1996-05-21 | — | — | US | disclosed |
| WO-1995024407-A1 | HETERO-ANNULATED INDAZOLES | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1995-09-14 | — | — | WO | disclosed |
| EP-0662076-A1 | 2-AMINOALKYL-5-AMINOALKYLAMINO SUBSTITUTED ISOQUINOINDAZOLE-6-(2H)-ONES WITH ANTITUMOUR ACTIVITY | THE UNIVERSITY OF VERMONT (US) | 1995-07-12 | — | — | EP | disclosed |
| CN-1101046-A | 2-aminoalkyl-5-aminoalkylamino substituted isoquinoindazole-6(2h)-ones | UNIV VERMONT (US) | 1995-04-05 | — | — | CN | disclosed |
| WO-1994006795-A1 | 2-AMINOALKYL-5-AMINOALKYLAMINO SUBSTITUTED ISOQUINOINDAZOLE-6-(2H)-ONES WITH ANTITUMOUR ACTIVITY | THE UNIVERSITY OF VERMONT (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466829-B2 | Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC2R, MC1R, MC3R | TDP1 4859/4885MEN1 1173/4885GAA 3392/4885 |
| US-12404281-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | TDP1 1421/4885MEN1 2490/4885GAA 4544/4885 |
| US-20260007754-A1 | Conjugate Molecules | CD274, PDCD1, PDCD1LG2 | TDP1 4187/4885MEN1 2032/4885GAA 2607/4885 |
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | CCNA1, KRAS, RSU1 | TDP1 1804/4885MEN1 364/4885GAA 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.